Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/bioscientifica/analysis-of-potential-response-predictors-to-capecitabine-temozolomide-ej0QI6OFQ5
References (22)
-
Y. Jonkers, S. Claessen, A. Perren, Sonja Schmid, P. Komminoth, A Verhofstad, L. Hofland, R. Krijger, Piet Slootweg, F Ramaekers, Ernst Speel (2005)
Chromosomal instability predicts metastatic disease in patients with insulinomas.Endocrine-related cancer, 12 2
-
Thomas Walter, Thomas Walter, B. Brakel, Cécile Vercherat, V. Hervieu, V. Hervieu, J. Forestier, J-A Chayvialle, J-A Chayvialle, Y. Molin, C. Lombard-Bohas, M-O Joly, M-O Joly, J. Scoazec, J. Scoazec (2015)
O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agentsBritish Journal of Cancer, 112
-
M. Cives, J. Strosberg (2014)
An update on gastroenteropancreatic neuroendocrine tumors.Oncology, 28 9
-
M. Hegi, A. Diserens, T. Gorlia, M. Hamou, N. Tribolet, N. Tribolet, M. Weller, J. Kros, J. Hainfellner, W. Mason, L. Mariani, Jacoline Bromberg, P. Hau, R. Mirimanoff, J. Cairncross, R. Janzer, R. Stupp (2005)
MGMT Gene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 352
-
R. Fine, A. Gulati, Benjamin Krantz, R. Moss, S. Schreibman, D. Tsushima, Kelley Mowatt, R. Dinnen, Yuehua Mao, P. Stevens, B. Schrope, J. Allendorf, James Lee, W. Sherman, J. Chabot (2013)
Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experienceCancer Chemotherapy and Pharmacology, 71
-
O. Chinot, M. Barrié, S. Fuentes, N. Eudes, Sophie Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P. Martin, H. Dufour, D. Figarella-Branger (2007)
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 12
-
A. Schmitt, M. Pavel, T. Rudolph, H. Dawson, A. Blank, P. Komminoth, E. Vassella, A. Perren (2014)
Prognostic and Predictive Roles of MGMT Protein Expression and Promoter Methylation in Sporadic Pancreatic Neuroendocrine NeoplasmsNeuroendocrinology, 100
-
P. Kunz (2015)
Carcinoid and neuroendocrine tumors: building on success.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 16
-
J. Strosberg, R. Fine, Junsung Choi, A. Nasir, D. Coppola, Dung-tsa Chen, J. Helm, L. Kvols (2011)
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomasCancer, 117
-
(2010)
Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In World Health Organization Classification of Tumours of the Digestive System, pp 13–14 -
K. Öberg, U. Knigge, D. Kwekkeboom, A. Perren (2012)
Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Annals of oncology : official journal of the European Society for Medical Oncology, 23 Suppl 7
-
Y. Jiao, C. Shi, B. Edil, R. Wilde, D. Klimstra, A. Maitra, R. Schulick, Laura Tang, elliot fishman, M. Choti, V. Velculescu, L. Diaz, B. Vogelstein, K. Kinzler, R. Hruban, N. Papadopoulos (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 331
-
D. Allred, G. Clark, R. Elledge, S. Fuqua, Richard Brown, G. Chamness, C. Osborne, W. McGuire (1993)
Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer.Journal of the National Cancer Institute, 85 3
-
I. Marinoni, Anja Kurrer, E. Vassella, M. Dettmer, T. Rudolph, V. Banz, Fabio Hunger, Silvan Pasquinelli, E. Speel, A. Perren (2014)
Loss of DAXX and ATRX are associated with chromosome instability and reduced survival of patients with pancreatic neuroendocrine tumors.Gastroenterology, 146 2
-
M. Kulke, K. Stuart, P. Enzinger, D. Ryan, Jeffrey Clark, A. Muzikansky, M. Vincitore, A. Michelini, C. Fuchs (2006)
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 3
-
C. Heaphy, R. Wilde, Y. Jiao, A. Klein, B. Edil, C. Shi, C. Bettegowda, F. Rodriguez, C. Eberhart, Sachidanand Hebbar, G. Offerhaus, R. McLendon, B. Rasheed, Yiping He, Hai Yan, D. Bigner, S. Oba-Shinjo, S. Marie, G. Riggins, K. Kinzler, B. Vogelstein, R. Hruban, A. Maitra, N. Papadopoulos, A. Meeker (2011)
Altered Telomeres in Tumors with ATRX and DAXX MutationsScience, 333
-
M. Kulke, J. Hornick, Christine Frauenhoffer, Susanne Hooshmand, D. Ryan, P. Enzinger, J. Meyerhardt, Jeffrey Clark, K. Stuart, C. Fuchs, M. Redston (2009)
O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine TumorsClinical Cancer Research, 15
-
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
-
M. Falconi, D. Bartsch, B. Eriksson, G. Klöppel, J. Lopes, J. O'Connor, R. Salazar, B. Taal, M. Vullierme, D. O’Toole (2011)
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning TumorsNeuroendocrinology, 95
-
Sara Ekeblad, A. Sundin, E. Janson, S. Welin, D. Granberg, Henrik Kindmark, K. Dunder, G. Kozlovacki, Håkan Örlefors, Mattias Sigurd, K. Öberg, B. Eriksson, B. Skogseid (2007)
Temozolomide as Monotherapy Is Effective in Treatment of Advanced Malignant Neuroendocrine TumorsClinical Cancer Research, 13
-
J. Chan, K. Stuart, C. Earle, Jeffrey Clark, P. Bhargava, R. Miksad, L. Blaszkowsky, P. Enzinger, J. Meyerhardt, Hui Zheng, C. Fuchs, M. Kulke (2012)
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 24
-
S. Gerson (2004)
MGMT: its role in cancer aetiology and cancer therapeuticsNature Reviews Cancer, 4
- Publisher
- Bioscientifica
- Copyright
- © 2016 Society for Endocrinology
- ISSN
- 1351-0088
- eISSN
- 1479-6821
- DOI
- 10.1530/erc-16-0147
- Publisher site
- See Article on Publisher Site
Abstract
The capecitabine and temozolomide (CAPTEM) regimen is active in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs), with response rates ranging from 30 to 70%. Small retrospective studies suggest that O6-methylguanine DNA methyltransferase (MGMT) deficiency predicts response to temozolomide. High tumor proliferative activity is also commonly perceived as a significant predictor of response to cytotoxic chemotherapy. It is unclear whether chromosomal instability (CIN), which correlates with alternative lengthening of telomeres (ALT), is a predictive factor. In this study, we evaluated 143 patients with advanced pNET who underwent treatment with CAPTEM for radiographic and biochemical response. MGMT expression (n=52), grade (n=128) and ALT activation (n=46) were investigated as potential predictive biomarkers. Treatment with CAPTEM was associated with an overall response rate (ORR) of 54% by RECIST 1.1. Response to CAPTEM was not influenced by MGMT expression, proliferative activity or ALT pathway activation. Based on these results, no biomarker-driven selection criteria for use of the CAPTEM regimen can be recommended at this time.
Journal
Endocrine Related Cancer – Bioscientifica
Published: Sep 1, 2016
Keywords: predictive factors